Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

Shannon L. Risacher; Noelia Fandos; Judith Romero; Ian Sherriff; P. Pesini; Andrew J. Saykin; Liana G. Apostolova

doi:10.1016/j.dadm.2019.05.007

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

Shannon L. Risacher^*, Noelia Fandos, Judith Romero, Ian Sherriff, P. Pesini, Andrew J. Saykin, Liana G. Apostolova

^*Corresponding author for this work

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

AbstractIntroductionWe investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET).MethodsForty‐four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty‐seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel‐wise basis were also evaluated.ResultsLower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD‐related regions on both regional and voxel‐wise analyses.DiscussionPlasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. Additional studies in larger samples are warranted.

Original language	English
Pages (from-to)	510-519
Number of pages	0
Journal	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Volume	11
Issue number	1
Early online date	27 Jul 2019
DOIs	https://doi.org/10.1016/j.dadm.2019.05.007
Publication status	Published - Dec 2019

Access to Document

10.1016/j.dadm.2019.05.007

Cite this

@article{c727a682bcb04bfbad66b3fdcaa4aea1,

title = "Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition",

abstract = "AbstractIntroductionWe investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET).MethodsForty‐four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty‐seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel‐wise basis were also evaluated.ResultsLower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD‐related regions on both regional and voxel‐wise analyses.DiscussionPlasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. Additional studies in larger samples are warranted.",

author = "Risacher, {Shannon L.} and Noelia Fandos and Judith Romero and Ian Sherriff and P. Pesini and Saykin, {Andrew J.} and Apostolova, {Liana G.}",

year = "2019",

month = dec,

doi = "10.1016/j.dadm.2019.05.007",

language = "English",

volume = "11",

pages = "510--519",

journal = "Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring",

issn = "2352-8729",

number = "1",

}

TY - JOUR

T1 - Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

AU - Risacher, Shannon L.

AU - Fandos, Noelia

AU - Romero, Judith

AU - Sherriff, Ian

AU - Pesini, P.

AU - Saykin, Andrew J.

AU - Apostolova, Liana G.

PY - 2019/12

Y1 - 2019/12

N2 - AbstractIntroductionWe investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET).MethodsForty‐four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty‐seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel‐wise basis were also evaluated.ResultsLower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD‐related regions on both regional and voxel‐wise analyses.DiscussionPlasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. Additional studies in larger samples are warranted.

AB - AbstractIntroductionWe investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET).MethodsForty‐four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty‐seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel‐wise basis were also evaluated.ResultsLower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD‐related regions on both regional and voxel‐wise analyses.DiscussionPlasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. Additional studies in larger samples are warranted.

U2 - 10.1016/j.dadm.2019.05.007

DO - 10.1016/j.dadm.2019.05.007

M3 - Article

SN - 2352-8729

VL - 11

SP - 510

EP - 519

JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

IS - 1

ER -

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

Abstract

Access to Document

Fingerprint

Cite this